Investigation of the usefulness of deucravacitinib in early onset psoriasis

未提供0 个研究点目标入组 100 人开始时间: 2025年2月14日最近更新: 2025年5月2日

适应症

试验速览

暂无简介。

•Psoriasis vulgaris patients over 18 years old
•Patients with psoriasis vulgaris less than 2 years or more than 10 years after onset
•Patients who have given a written explanation of the study and obtained written consent to participate in the study.
•Patients who fulfill any of the following (1)~(3)
•(1)Patients who do not respond adequately to existing systemic therapies, including phototherapy, and whose skin rash covers more than 10% of their body surface area
•(2)Patients with severely impaired quality of life: DLQI > 10
•(3)Patients with refractory skin rashes:
•Patients with skin rash on difficult-to-treat areas (scalp, palms, soles, genitalia, etc.) and PASI 5 or higher

•Patients who have been treated with multiple biologics(However, only one type of experience in the use of biological products is acceptable for registration.)
•Patients who have been previously treated with the investigational drug deucravacitinib and were unable to continue treatment for safety or other reasons
•Patients with serious infections and active tuberculosis
•Patients with a history of hypersensitivity to any component of the drugs under study
•Patients who have participated or are participating in a clinical trial within the past 6 months
•Patients deemed ineligible by the physician in charge

Percentage achieving PASI >= 90 or PASI score <=1

时间窗: 24 weeks of treatment

Patients with psoriasis less than 2 years after onset (Group A) vs. patients with psoriasis more than 10 years after onset (Group B)

发起方

未提供